Pancreatic Cancer Research

ResearcherMedical College of WisconsinActive in the last 2 years

Callisia Nathelee Clarke

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-5229-961X; OpenAlex author ID A5048023467. Sources: OpenAlex.

Their work

Papers
16 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
34
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: 2 papers · 2020: 4 papers · 2021: 1 paper · 2022: none · 2023: 3 papers · 2024: 2 papers · 2025: 1 paper · 2026: 2 papers

Papers 16

  1. AI-Derived Electronic Tumor Marker For Cancer Antigen 19-9 Nonproducers With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2026.0291↗
  2. Perioperative Chemotherapy and Total Neoadjuvant Chemotherapy for Pancreatic Adenocarcinoma. First author DOI 10.1016/j.soc.2025.05.003↗
  3. Patterns of Locoregional Pancreatic Cancer Recurrence After Total Neoadjuvant Therapy and Implications on Optimal Neoadjuvant Radiation Treatment Volumes. Co-author DOI 10.1016/j.prro.2024.07.001↗
  4. Characterization of an oligometastatic state in patients with metastatic pancreatic adenocarcinoma undergoing systemic chemotherapy. Co-author DOI 10.1002/cam4.6582↗
  5. Chemotherapy-free treatment targeting fusions and driver mutations in KRAS wild-type pancreatic ductal adenocarcinoma, a case series. Co-author DOI 10.1177/17588359241253113↗
  6. Neoadjuvant chemotherapy for pancreatic cancer: Quality over quantity. Co-author DOI 10.1002/jso.27265↗
  7. Biliary Adverse Events During Neoadjuvant Therapy for Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000005884↗
  8. CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/Nab-Paclitaxel for Patients with Operable Pancreatic Cancer. Co-author DOI 10.1245/s10434-022-13055-1↗
  9. Total Neoadjuvant Therapy for Operable Pancreatic Cancer. Co-author DOI 10.1245/s10434-020-09149-3↗
  10. Detection of germline variants using expanded multigene panels in patients with localized pancreatic cancer. Co-author DOI 10.1016/j.hpb.2020.03.022↗
  11. Radiographic patterns of first disease recurrence after neoadjuvant therapy and surgery for patients with resectable and borderline resectable pancreatic cance… Co-author DOI 10.1016/j.surg.2020.04.031↗
  12. Impact of Neoadjuvant Chemoradiation on Pathologic Response in Patients With Localized Pancreatic Cancer. Co-author DOI 10.3389/fonc.2020.00460↗
  13. Value of Pretreatment 18F-fluorodeoxyglucose Positron Emission Tomography in Patients With Localized Pancreatic Cancer Treated With Neoadjuvant Therapy. Co-author DOI 10.3389/fonc.2020.00500↗
  14. Survival of patients with borderline resectable pancreatic cancer who received neoadjuvant therapy and surgery. Co-author DOI 10.1016/j.surg.2019.05.010↗
  15. Management of Acute Cholecystitis during Neoadjuvant Therapy in Patients with Pancreatic Adenocarcinoma. Co-author DOI 10.1245/s10434-019-07906-7↗
  16. Is Adjuvant Therapy Necessary for All Patients with Localized Pancreatic Cancer Who Have Received Neoadjuvant Therapy? Co-author DOI 10.1007/s11605-017-3544-5↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kathleen K. Christians · 15 shared papers, 2017–2026 · strength 2.00
  2. William Adrian Hall · 14 shared papers, 2017–2026 · strength 1.91
  3. Douglas B. Evans · 14 shared papers, 2017–2025 · strength 1.77
  4. Susan Tsai · 14 shared papers, 2017–2025 · strength 1.77
  5. Mohammed Aldakkak · 13 shared papers, 2017–2026 · strength 1.72
  6. Mandana Kamgar · 9 shared papers, 2020–2026 · strength 1.48
  7. Bradley A. Erickson · 12 shared papers, 2017–2024 · strength 1.39
  8. Ben George · 12 shared papers, 2017–2024 · strength 1.39
  9. Sam Z. Thalji · 5 shared papers, 2023–2026 · strength 1.34
  10. Kulwinder S. Dua · 6 shared papers, 2019–2025 · strength 0.80
  11. Beth E. Erickson · 3 shared papers, 2024–2026 · strength 0.60
  12. Paul S. Ritch · 6 shared papers, 2017–2020 · strength 0.53
  13. Naveen M. Kulkarni · 4 shared papers, 2020–2023 · strength 0.47
  14. Chad A. Barnes · 5 shared papers, 2017–2020 · strength 0.43
  15. Ben George · 2 shared papers, 2024–2025 · strength 0.38
  16. Parag P. Tolat · 3 shared papers, 2019–2023 · strength 0.35
  17. Nikki K. Lytle · 1 shared paper, 2026 · strength 0.22
  18. Anai N. Kothari · 1 shared paper, 2026 · strength 0.22
  19. Douglas B. Evans · 1 shared paper, 2026 · strength 0.22
  20. Ben George · 1 shared paper, 2026 · strength 0.22
  21. Jordan R. Kharofa · 1 shared paper, 2025 · strength 0.20
  22. Sara Beltrán Ponce · 1 shared paper, 2025 · strength 0.20
  23. E.S. Paulson · 1 shared paper, 2025 · strength 0.20
  24. Neil R. Jariwalla · 2 shared papers, 2019–2020 · strength 0.18
  25. Maahum Mehdi · 1 shared paper, 2024 · strength 0.18

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.